Skye accuses Spectral of allegedly running a spoiling campaign to scupper IPO (initial public offering)
This article was originally published in Clinica
Executive Summary
Canadian diagnostics company Skye Pharmatech has filed suit in an Ontario court, claiming that an alleged campaign orchestrated by some of the board of directors of a rival Canadian diagnostic company, Spectral Diagnostics, derailed Skye's initial public offering (IPO) in March. The IPO achieved less than a third of its expected sum - raising just Can+ACQ-1.8 million rather than the predicted Can+ACQ-6.5 million. Spectral has vehemently denied the claim and says that it will fight the lawsuit vigorously.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.